Affiliations: [a] Gynecologic Oncology, Washington University School of Medicine, 4911 Barnes Jewish Hospital Plaza, St. Louis, MO, USA | [b] Department of Gynecologic Oncology, M.D. Anderson Cancer Center, Houston, TX, USA | [c] Department of Cancer Biology, M.D. Anderson Cancer Center, Houston, TX, USA | [d] Center for RNA Interference and Non-Coding RNA, M.D. Anderson Cancer Center, Houston, TX, USA | [x] Department of Breast medical Oncology, M.D. Anderson Cancer Center, Houston, TX, USA | [y] Department of Gynecologic Oncology, M.D. Anderson Cancer Center, Houston, TX, USA
Correspondence:
[*]
Corresponding authors: Lois M. Ramondetta, Department of Gynecologic Oncology, M.D. Anderson Cancer Center, 1155 Herman Pressler Unit 1362, Houston, TX 77030, USA. Tel.: +1 713 745 0307; Fax: +1 713 792 7586; E-mail: [email protected]; Premal H. Thaker, Division of Gynecologic Oncology, Washington University School of Medicine, 4911 Barnes Jewish Hospital Plaza, St. Louis, MO 63110, USA. Tel.: +1 314 362 3181; Fax: +1 314 362 2893; E-mail: [email protected].
Abstract: The importance of adrenergic pathways in cancer has long been suspected, but now there is mounting epidemiological, preclinical, and clinical evidence of its importance in gynecologic cancers. To date, most of these effects are mediated primarily through the beta 2 adrenergic receptor activation of the tumor cell cyclic AMP-protein kinase A signaling pathway. This review will discuss the current knowledge about the neuroendocrine stress response in gynecologic tumor biology.
